Muscle & growth hormone
Sermorelin: published research
Also known as GRF (1-29) NH2
The first 29 amino acids of GHRH — the shortest part of the hormone that is still fully active. It was one of the first compounds of its type tested in people; studies measured growth-hormone release in children with low growth hormone and in older adults.
Evidence at a glance
4 studies 1989–1999
- 3 Human trial
- 1 Review
What researchers look at
- GHRH signalling
- Growth-hormone release
- Childhood growth
- Ageing
What is still unknown
Most human studies are older and small; modern long-term data are limited.
Studies in people
3- Human trial
In an open-label multicentre study of 110 prepubertal children with GH deficiency, GHRH(1-29) (sermorelin) increased growth rate over one year and was well tolerated.
Thorner M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. The Journal of Clinical Endocrinology and Metabolism. 1996. PMID 8772599
- Human trial
In healthy older men, 14 days of GHRH(1-29) injections raised 24-hour GH and IGF-I levels to values no different from those of young men.
Corpas E, et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. The Journal of Clinical Endocrinology and Metabolism. 1992. PMID 1379256
- Human trial
In eight children aged 6–9 years with partial GH insufficiency, continuous subcutaneous infusion of GHRH(1-29)NH2 (sermorelin) increased GH secretion and growth velocity after 3 and 6 months; no control group was reported.
Brain C, et al. Use of continuous subcutaneous growth hormone-releasing hormone (GHRH (1-29)NH2) infusions to augment growth hormone secretion and to promote growth. Acta Paediatrica Scandinavica. Supplement. 1989. PMID 2546369
Reviews
1- Review
Review of sermorelin for diagnosing and treating GH deficiency in children, reporting sustained gains in growth rate and good tolerability based on limited data.
Prakash A, et al. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. PMID 18031173
Short summaries of published studies, with links to the original papers. Results in animals or cells may not apply to people. This is not medical advice and not a guide to use.